Arvinas Inc

Change company Symbol lookup

Select an option...

ARVN Arvinas Inc

FOUR Shift4 Payments Inc

UK Ucommune International Ltd

CRDF Cardiff Oncology Inc

TRNR Interactive Strength Inc

OMGA Omega Therapeutics Inc

ACST Acasti Pharma Inc

PYPD PolyPid Ltd

ACRX AcelRx Pharmaceuticals Inc

MI Nft Ltd

Go

Arvinas, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. The Company uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three product candidates include ARV-110, ARV-471 and ARV-766. It develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). It develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. The Company develops ARV-766, a PROTAC protein degrader for the treatment of men with mCRPC.